Bone metabolism results from a balance between osteoclast-driven bone resorption and osteoblast-mediated bone formation. Diseases such as periodontitis and rheumatoid arthritis are characterized by increased bone destruction due to enhanced osteoclastogenesis 1,2 . Here we report that interferon regulatory factor-8 (IRF-8), a transcription factor expressed in immune cells, is a key regulatory molecule for osteoclastogenesis. IRF-8 expression in osteoclast precursors was downregulated during the initial phase of osteoclast differentiation induced by receptor activator of nuclear factor-κB ligand (RANKL), which is encoded by the Tnfsf11 gene. Mice deficient in Irf8 showed severe osteoporosis, owing to increased numbers of osteoclasts, and also showed enhanced bone destruction after lipopolysaccharide (LPS) administration. Irf8 −/− osteoclast precursors underwent increased osteoclastogenesis in response to RANKL and tumor necrosis factor- (TNF-). IRF-8 suppressed osteoclastogenesis by inhibiting the function and expression of nuclear factor of activated T cells c1 (NFATc1). Our results show that IRF-8 inhibits osteoclast formation under physiological and pathological conditions and suggest a model where downregulation of inhibitory factors such as IRF-8 contributes to RANKL-mediated osteoclastogenesis.
Osteoclasts are multinucleated giant cells derived from the monocyte and macrophage lineage. Their differentiation is triggered by RANKL in the presence of macrophage colony-stimulating factor (M-CSF, encoded by the Csf1 gene), which is produced by osteoblasts 1, 2 . RANKL induces intracellular signals via its receptor RANK, and it upregulates the expression of various genes, such as Nfatc1, Fos, Oscar, Ctsk and Calcr, which encode NFATc1, c-Fos, osteoclastassociated receptor (OSCAR), cathepsin K and calcitonin receptor, respectively [3] [4] [5] . Numerous studies have focused on these upregulated genes and their roles in osteoclastogenesis. However, the expression of various genes is also simultaneously downregulated during osteoclastogenesis 6 . The biological role of the downregulated expression of these genes after RANK activation, has not been fully elucidated.
To identify genes that show reduced expression in response to RANK signaling, we performed a genome-wide screen of messenger RNAs from osteoclast precursors and osteoclasts using a DNA microarray technique (data deposited in the Gene Expression Omnibus). Among the identified genes, we found that expression of the transcription factor Irf8 was reduced to one-quarter during the initial phase of osteoclastogenesis triggered by RANKL. IRF-8 is known to be specifically expressed in immune cells, including monocytes and macrophages, B lymphocytes and activated T lymphocytes [7] [8] [9] . It is a member of the IRF family and has been shown to regulate myeloid cell development by interacting with Ets family transcription factors 10, 11 . Hence, Irf8 −/− mice show a large number of myeloid progenitors, defects in macrophage function including impaired interleukin-12 production, developmental defects in CD8α + and plasmacytoid dendritic cells, and systemic expansion of the granulocyte population, which frequently leads to a fatal blast crisis [12] [13] [14] .
Using RT-PCR and immunoblot analysis, we detected Irf8 expression in bone marrow-derived macrophages (BMMs) and spleen-derived macrophages prepared from wild-type mice, which are capable of differentiating into osteoclasts (Fig. 1a,b) . As previously shown 3 , Nfatc1 was modestly expressed at a basal level in unstimulated BMMs, and Nfatc1 expression was strongly induced after RANKL stimulation (Fig. 1b) ; robust induction of NFATc1 by RANKL is a necessary and pivotal step for osteoclast differentiation characterized by enhanced expression of osteoclast marker genes such as Oscar, Itgb3 (encoding integrin β 3 protein) and Ctsk (ref. 3) . In contrast, Irf8 expression was lower after RANKL stimulation (Fig. 1a,b) , resulting in substantially lower nuclear Irf-8 protein 24 h after RANKL addition (Fig. 1b) . We hypothesized that IRF-8 downregulation may be required for osteoclast differentiation and that IRF-8 may inhibit early stages of osteoclastogenesis.
To examine the role of IRF-8 in osteoclastogenesis, we constructed a retroviral vector, pMX-Irf8-IRES-EGFP, which was engineered to express both Irf-8 and EGFP downstream of an internal ribosomal zymosan particles, whereas multinucleated osteoclasts failed to do so (Fig. 1d) . These results suggest that IRF-8 inhibits osteoclastogenesis from precursor cells, which instead retain the characteristics of phagocytic macrophages.
Next, we analyzed the Irf8 −/− mice for abnormal bone phenotypes. Radiographic and microcomputed tomographic analyses showed that these mice had severe osteoporosis accompanied by markedly lower trabecular bone volume, number, and thickness, as well as a smaller (h) Bone morphometric analysis of femurs isolated from chimeric mice. Representative data from one of two independent experiments is shown (n = 3 (WT) and 3 (Irf8 −/− )) in each experiment. n = 3. **P < 0.01; *P < 0.05. Error bars represent means ± s.d.
WT Irf8 (Fig. 2a,b) . Histomorphometric analysis also revealed reduced bone mass in the Irf8 −/− mice (data not shown). Notably, we observed higher osteoclast numbers and larger osteoclast surface areas in these mice (Fig. 2c ). There were no significant differences between wild-type and Irf8 −/− mice in the serum concentration of osteoprotegerin, a decoy RANKL receptor that inhibits osteoclastogenesis, or in RANKL levels in primary cultured osteoblasts (Supplementary Fig. 1 ). Moreover, we observed a higher rate of bone formation accompanying the accelerated bone resorption rate in the Irf8 −/− mice, suggesting that their osteoporosis was caused by enhanced bone turnover and remodeling (Fig. 2d) . Together, these observations indicate that IRF-8 has a suppressive role in osteoclastogenesis during in vivo bone remodeling. To address whether the bone phenotype could be explained by Irf8 deficiency in osteoclast precursors or whether Irf8 deficiency in osteoblasts or bone marrow stromal cells could play a part, we established chimeric mouse models in which we transplanted either wild-type or Irf8 −/− littermate bone marrow into lethally irradiated wild-type recipients. Consistent with the results in Irf8-knockout mice, Irf8 −/− bone marrow chimeric mice showed severe, high-turnover osteoporosis ( Fig. 2e-h) . Further, IRF-8 is mainly expressed in hematopoietic cells [7] [8] [9] and, indeed, we did not detect Irf8 expression in primary calvarial osteoblasts (data not shown). Lastly, primary Irf8 −/− osteoblast differentiation and matrix calcification were not affected compared to wild-type cells (Supplementary Fig. 2) . Thus, the osteoporosis resulted from enhanced osteoclastogenesis, which is a cell autonomous consequence of Irf8 deficiency in osteoclast precursors but not osteoblasts.
On the basis of these results, we examined the differentiation potential of osteoclast precursors obtained from Irf8 −/− mice. When we cultured wild-type or Irf8 −/− osteoclast precursors with wild-type or Irf8 −/− primary osteoblasts in the presence of active vitamin D 3 (an inducer of RANKL expression in osteoblasts), a larger number of osteoclasts formed from the Irf8 −/− precursors than from the wildtype cells, independent of whether the osteoblasts were from Irf8 −/− or wild-type mice (Fig. 3a) . These data further support the notion that there is no difference between wild-type and Irf8 −/− osteoblasts in their ability to induce osteoclastogenic activity and that Irf8 deficiency in osteoclast precursors has a decisive role in promoting osteoclast differentiation. Indeed, macrophage cultures prepared from Irf8 −/− mice also showed augmented osteoclastogenesis in the presence of RANKL and M-CSF (Fig. 3b) , which led to an increase in resorption on dentin slices in vitro (data not shown). In contrast, retrovirusmediated reconstitution of Irf8 expression in Irf8 −/− macrophages inhibited RANKL-induced osteoclastogenesis (Fig. 3c) . These results indicate that IRF-8 in osteoclast precursors is involved in the inhibition of osteoclastogenesis in vitro and in vivo. Furthermore, we found that IRF-8 expression was also lower during RANKL-induced human osteoclastogenesis, although with slower kinetics (Fig. 3d) . Silencing of IRF8 mRNA in human osteoclast precursors with small interfering RNAs (siRNAs) resulted in enhanced osteoclast differentiation (Fig. 3e-f) , indicating that the function of IRF-8 in osteoclastogenesis is well conserved in humans and mice.
Consistent with the results regarding osteoclastogenesis, the mRNA expression profiles of various osteoclast markers were more strongly upregulated by RANKL stimulation in macrophages prepared from Irf8 −/− mice than in those obtained from wild-type mice (Supplementary Fig. 3 ). However, Tnfrsf11a and Csf1r (encoding Rank and M-Csf receptor protein, respetively) mRNA expression and cell surface Rank protein expression were comparable in wild-type Fig. 4b ). These results suggest that enhanced osteoclastogenesis in Irf8 −/− macrophages is not due to changes in these receptor levels. Expression of the Nfatc1 gene and the osteoclast marker Acp5, which encodes tartrate-resistant acid phosphatase (TRAP), in Irf8 −/− precursors was induced by concentrations of RANKL that were 5-25% of those required for the expression of the genes in wild-type precursors (Fig. 4a) . Furthermore, overexpression of Irf8 in the precursor cells repressed the RANKL-induced expression of Nfatc1 and Acp5 mRNAs (Fig. 4b) .
These observations led us to examine the effect of IRF-8 on the transcriptional activity of NFATc1, which was previously reported to interact with . For these experiments, we used luciferase reporter plasmids driven by three copies of the NFATc1 binding site from the human IL2 (encoding interleukin-2) distal promoter (p3x Nfatc1-Luc) or by the mouse Acp5 promoter (pAcp5-Luc). Overexpression of Nfatc1 gene activated these promoters, whereas simultaneous expression of Irf8 gene reduced the activities of the promoters to control levels (Fig. 4c) , indicating that IRF-8 inhibits the transcriptional activity of NFATc1.
When GST-tagged Irf-8 proteins were incubated with nuclear lysates containing Flag-hemagglutinin-tagged Nfatc1 (FH-Nfatc1), addition of Flag-specific antibodies to the mixture resulted in the immunoprecipitation of GST-Irf-8 with FH-Nfatc1, suggesting that IRF-8 physically interacts with NFATc1 (Fig. 4d) . Furthermore, we identified an association between endogenous IRF-8 and NFATc1 by coimmunoprecipitation from nuclear extracts of human monocytic cells ( Supplementary  Fig. 5 ). We further examined the effects of Irf-8 on the binding of Nfatc1 to its target DNA elements in an electrophoretic mobility shift assay (EMSA). We detected Nfatc1-DNA complexes, which we confirmed by adding competitive probes or NFATc1-specific antibodies (Fig. 4e) . When we increased the levels of GST-Irf-8 (Fig. 4e) or added nuclear lysates containing excess Irf-8 (Fig. 4f) in the reaction mixture, Nfatc1 binding to the labeled probes was substantially diminished, demonstrating the inhibitory effect of IRF-8 on NFATc1 binding to its target DNA elements.
We then attempted to examine the roles of IRF-8 in the processes underlying pathological bone destruction. Because several members of the IRF family of transcription factors, including IRF-8, have been shown to be crucial in Toll-like receptor (TLR) signaling in response to such microbial components as LPS and unmethylated CpG DNA 16, 17 , we examined the role of IRF-8 in the bone destruction l e t t e r s observed during TLR-mediated inflammation. Administration of LPS to the calvarial periosteum resulted in enhanced osteoclast formation in wild-type mice, whereas more extensive bone destruction was observed in Irf8 −/− mice (Fig. 4g) . These results suggest that IRF-8 is a major negative regulator of osteoclastogenesis and a mediator of the maintenance of bone integrity during inflammatory bone destruction. We also examined the effects of TLR ligands on osteoclastogenesis in wild-type and Irf8 −/− osteoclast precursors. As previously reported 18 , LPS at high doses completely inhibited RANKL-induced osteoclastogenesis in wild-type cell cultures. In contrast, corresponding high doses of LPS, and also of the TLR3 ligand poly(I:C) and the TLR9 ligand CpG DNA, only partially inhibited osteoclast differentiation in Irf8 −/− cell cultures ( Fig. 4h and Supplementary  Fig. 6 ). Irf8-deficient cells were almost completely refractory to the inhibitory effects of the TLR2 ligand peptidoglycan ( Supplementary  Fig. 6a) . These results suggest a potential inhibitory role of IRF-8 in the regulation of osteoclastogenesis by TLRs, although TLRs can also activate IRF-8-independent inhibitory mechanisms. We further found that expression of Ifna and Ifnb mRNAs (encoding Ifn-α and Ifn-β, respectively) was not diminished in Irf8-deficient cells and that IFN-γ completely inhibited osteoclastogenesis in Irf8 −/− macrophages, similar to wild-type cells (data not shown), thus suggesting that IRF-8 can inhibit osteoclastogenesis independently of IFN-γ. Finally, we examined the effect of TNF-α on osteoclastogenesis using Irf8 −/− precursors, because TNF-α is a major mediator of inflammation induced by TLRs [19] [20] [21] and has been suggested to be able to induce osteoclastogenesis [22] [23] [24] . Consistent with previous reports, TNF-α induced the development of a small number of osteoclasts in cultures of wild-type precursor cells (Fig. 4i) . Notably, osteoclastogenesis was enhanced in cultures of Irf8 −/− precursor cells treated with TNF-α (Fig. 4i) . The mRNA expression levels of Nfatc1 and Acp5 in the Irf8 −/− osteoclast precursors were also augmented by TNF-α (Fig. 4j) , indicating that IRF-8 also has a suppressive role in TNF-α-induced osteoclastogenesis.
Our data provide a mechanism by which IRF-8 suppresses osteoclastogenesis (depicted in Supplementary Fig. 7) . In osteoclast precursors, abundant IRF-8 interacts with basally expressed NFATc1 to suppress its transcriptional activity and thus prevent its activation of target genes, including autoamplification of its own promoter. Stimulation of osteoclast precursors with RANKL results in the activation of nuclear factor-κB (NF-κB) and activator protein-1 (AP-1) that bind the Nfatc1 promoter to induce its activity. At the same time, RANKL induces the downregulation of IRF-8, thereby releasing NFATc1 from IRF-8-mediated suppression and augmenting NFATc1-mediated autoamplification of its own expression. Together, these mechanisms result in robust NFATc1 expression and induction of downstream genes required for osteoclast differentiation.
Bone erosion that occurs in the setting of infection and chronic inflammation, termed inflammatory osteolysis, contributes to the pathogenesis of infectious and inflammatory diseases such as rheumatoid arthritis 25 . Inflammatory bone erosion is driven by microbial products such as LPS and inflammatory cytokines, including TNF-α, that activate osteoclastogenesis directly or indirectly via activation of stromal cells and osteoblasts 25 . Our findings show that IRF-8 is crucial in attenuating LPS-induced inflammatory bone resorption and LPS-and TNF-α-induced osteoclastogenesis. This homeostatic role of IRF-8 may be required during acute infections and also in chronic inflammatory conditions such as rheumatoid arthritis. Identification of additional factors and mechanisms that augment IRF-8 expression or function may represent a fruitful clinical approach to therapeutic suppression of inflammatory bone erosion.
Overall, our findings support a model of RANKL-induced NFATc1 expression and osteoclast differentiation that involves cooperation between RANKL-mediated induction of positive regulators of osteoclastogenesis and suppression of negative regulators of osteoclast differentiation, such as IRF-8.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
